Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, vol.395, pp.1054-62, 2020. ,
Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis, Int J Infect Dis, 2020. ,
Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, 2020. ,
Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China, Ann Oncol, 2020. ,
Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan ,
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol, vol.21, pp.335-342, 2020. ,
Risk factors of healthcare workers with corona virus disease 2019: a retrospective cohort study in a designated hospital of Wuhan in China, Clin Infect Dis, 2020. ,
Coronavirus disease 2019: coronaviruses and blood safety, Transfus Med Rev, 2020. ,
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, vol.30, pp.269-71, 2020. ,
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun, vol.11, p.222, 2020. ,
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus, J Biol Chem, 2020. ,
A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, 2020. ,
In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, 2020. ,
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, vol.6, p.16, 2020. ,
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab, Blood Adv, vol.4, pp.1307-1317, 2020. ,
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality, Int J Antimicrob Agents, vol.2020, p.105954 ,
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target, Intensive Care Med, vol.46, pp.586-90, 2020. ,
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19, N Engl J Med, 2020. ,
Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertenison hospitalized with COVID-19, Circ Res, 2020. ,
Preparing for the unthinkable: emergency preparedness for the hematopoietic cell transplant program, Biol Blood Marrow Transpl, vol.12, pp.1229-1267, 2006. ,